Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial

被引:851
作者
Nogueira, Raul G. [1 ,2 ,3 ]
Lutsep, Helmi L. [4 ]
Gupta, Rishi [1 ,2 ,3 ]
Jovin, Tudor G. [5 ]
Albers, Gregory W. [6 ]
Walker, Gary A. [7 ]
Liebeskind, David S. [8 ]
Smith, Wade S. [9 ]
机构
[1] Emory Univ, Sch Med, Marcus Stroke & Neurosci Ctr, Dept Neurol,Grady Mem Hosp, Atlanta, GA 30303 USA
[2] Emory Univ, Sch Med, Marcus Stroke & Neurosci Ctr, Dept Neurosurg,Grady Mem Hosp, Atlanta, GA 30303 USA
[3] Emory Univ, Sch Med, Marcus Stroke & Neurosci Ctr, Dept Radiol,Grady Mem Hosp, Atlanta, GA 30303 USA
[4] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
[5] Univ Pittsburgh, Dept Neurol, Med Ctr, UPMC Stroke Ctr, Pittsburgh, PA 15260 USA
[6] Stanford Univ, Med Ctr, Dept Neurol, Stanford Stroke Ctr, Palo Alto, CA 94304 USA
[7] Stryker Neurovasc, Dept Clin Res, Mountain View, CA USA
[8] Univ Calif Los Angeles, Dept Neurol, UCLA Stroke Ctr, Los Angeles, CA 90024 USA
[9] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA
关键词
TISSUE-PLASMINOGEN ACTIVATOR; RT-PA STROKE; RECANALIZATION; THROMBOLYSIS; EFFICACY; DISEASE; DEVICES; SAFETY;
D O I
10.1016/S0140-6736(12)61299-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Present mechanical devices are unable to achieve recanalisation in up to 20-40% of large vessel occlusion strokes. We compared efficacy and safety of the Trevo Retriever, a new stent-like device, with its US Food and Drug Administration-cleared predecessor, the Merci Retriever. Methods In this open-label randomised controlled trial, we recruited patients at 26 sites in the USA and one in Spain. We included adults aged 18-85 years with angiographically confirmed large vessel occlusion strokes and US National Institutes of Health Stroke Scale (NIHSS) scores of 8-29 within 8 h of symptom onset. We randomly assigned patients (1:1) with sequentially numbered sealed envelopes to thrombectomy with Trevo or Merci devices. Randomisation was stratified by age (<= 68 years vs 69-85 years) and NIHSS scores (<= 18 vs 19-29) with alternating blocks of various sizes. The primary efficacy endpoint, assessed by an unmasked core laboratory, was thrombolysis in cerebral infarction (TICI) scores of 2 or greater reperfusion with the assigned device alone. The primary safety endpoint was a composite of procedure-related adverse events. Analyses were done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01270867. Findings Between Feb 3, 2011, and Dec 1, 2011, we randomly assigned 88 patients to the Trevo Retriever group and 90 patients to Merci Retriever group. 76 (86%) patients in the Trevo group and 54 (60%) in the Merci group met the primary endpoint after the assigned device was used (odds ratio 4.22, 95% CI 1.92-9.69; p(superiority) < 0.0001). Incidence of the primary safety endpoint did not differ between groups (13 [15%] patients in the Trevo group vs 21 [23%] in the Merci group; p=0.1826). Interpretation Patients who have had large vessel occlusion strokes but are ineligible for (or refractory to) intravenous tissue plasminogen activator should be treated with the Trevo Retriever in preference to the Merci Retriever.
引用
收藏
页码:1231 / 1240
页数:10
相关论文
共 23 条
  • [1] Neurothrombectomy Devices for the Treatment of Acute Ischemic Stroke: State of the Evidence
    Baker, William L.
    Colby, Jennifer A.
    Tongbram, Vanita
    Talati, Ripple
    Silverman, Isaac E.
    White, C. Michael
    Kluger, Jeffrey
    Coleman, Craig I.
    [J]. ANNALS OF INTERNAL MEDICINE, 2011, 154 (04) : 243 - 252
  • [2] Hemorrhagic transformation of ischemic brain tissue -: Asymptomatic or symptomatic?
    Berger, C
    Fiorelli, M
    Steiner, T
    Schäbitz, WR
    Bozzao, L
    Bluhmki, E
    Hacke, W
    von Kummer, R
    [J]. STROKE, 2001, 32 (06) : 1330 - 1335
  • [3] Low Rates of Acute Recanalization With Intravenous Recombinant Tissue Plasminogen Activator in Ischemic Stroke Real-World Experience and a Call for Action
    Bhatia, Rohit
    Hill, Michael D.
    Shobha, Nandavar
    Menon, Bijoy
    Bal, Simerpreet
    Kochar, Puneet
    Watson, Tim
    Goyal, Mayank
    Demchuk, Andrew M.
    [J]. STROKE, 2010, 41 (10) : 2254 - 2258
  • [4] PROVING THE NULL HYPOTHESIS IN CLINICAL-TRIALS
    BLACKWELDER, WC
    [J]. CONTROLLED CLINICAL TRIALS, 1982, 3 (04): : 345 - 353
  • [5] Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial
    Furlan, A
    Higashida, R
    Wechsler, L
    Gent, M
    Rowley, H
    Kase, C
    Pessin, M
    Ahuja, A
    Callahan, F
    Clark, WM
    Silver, F
    Rivera, F
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2003 - 2011
  • [6] Hacke W, 2004, LANCET, V363, P768
  • [7] Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
    Hacke, Werner
    Kaste, Markku
    Bluhmki, Erich
    Brozman, Miroslav
    Davalos, Antoni
    Guidetti, Donata
    Larrue, Vincent
    Lees, Kennedy R.
    Medeghri, Zakaria
    Machnig, Thomas
    Schneider, Dietmar
    von Kummer, Ruediger
    Wahlgren, Nils
    Toni, Danilo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) : 1317 - 1329
  • [8] Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke
    Higashida, RT
    Furlan, AJ
    [J]. STROKE, 2003, 34 (08) : E109 - E137
  • [9] Endovascular treatment of carotid embolic occlusions has a higher recanalization rate compared with cardioembolic occlusions
    Hussain, M. S.
    Lin, R.
    Cheng-Ching, E.
    Jovin, T. G.
    Moskowitz, S. I.
    Bain, M.
    Horowitz, M.
    Gupta, R.
    [J]. JOURNAL OF NEUROINTERVENTIONAL SURGERY, 2010, 2 (01) : 71 - 73
  • [10] Utilization of intravenous tissue plasminogen activator for acute ischemic stroke
    Katzan, IL
    Hammer, MD
    Hixson, ED
    Furlan, AJ
    Abou-Chebl, A
    Nadzam, DM
    [J]. ARCHIVES OF NEUROLOGY, 2004, 61 (03) : 346 - 350